Hyperion DeFi (NASDAQ:HYPD) Director Ellen Strahlman Purchases 3,601 Shares

Hyperion DeFi, Inc. (NASDAQ:HYPD) Director Ellen Strahlman acquired 3,601 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average cost of $3.86 per share, for a total transaction of $13,899.86. Following the acquisition, the director owned 79,049 shares in the company, valued at $305,129.14. This represents a 4.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Hyperion DeFi Price Performance

HYPD traded down $0.13 on Tuesday, reaching $3.37. The stock had a trading volume of 193,370 shares, compared to its average volume of 1,525,525. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $27.53 million, a price-to-earnings ratio of -0.83 and a beta of 2.81. Hyperion DeFi, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $17.99. The firm has a 50-day moving average of $4.87 and a 200-day moving average of $7.60.

Hyperion DeFi (NASDAQ:HYPD) last announced its quarterly earnings results on Friday, November 14th. The company reported $0.05 EPS for the quarter. The firm had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative return on equity of 119.59% and a negative net margin of 62,238.41%. As a group, sell-side analysts anticipate that Hyperion DeFi, Inc. will post -41.6 EPS for the current year.

Wall Street Analysts Forecast Growth

HYPD has been the subject of several analyst reports. Chardan Capital set a $7.75 price target on shares of Hyperion DeFi and gave the company a “buy” rating in a research note on Wednesday, December 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Wall Street Zen raised Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Cantor Fitzgerald started coverage on Hyperion DeFi in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target on the stock. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $4.58.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.